3 medicines that moved to the next trial phase this week
3 medicines from company sponsors entered a higher trial phase in trials registered on ClinicalTrials.gov from 3 November 2026 to 9 November 2026; the 3 below lead by phase and trial size.
As of . Research from public records, not investment advice.
- SHR-3167 (Jiangsu HengRui Medicine Co., Ltd.): First Phase 3 trial, after Phase 2 trials. Diabetes Mellitus, Type 2, 680 participants planned.
- Navepegritide (Ascendis Pharma A/S): First Phase 3 trial, after Phase 2 trials. Hypochondroplasia, 81 participants planned.
- 0.5% AR100DP1 (Arjil Pharmaceuticals LLC): First Phase 2 trial, after Phase 1/2 trials. Dermatitis Atopic, 40 participants planned.
How this list is made
A medicine counts when a company sponsor registers a trial of it on ClinicalTrials.gov at a higher phase (Phase 2, 2/3 or 3) than any of its earlier trials of the same drug, on ClinicalTrials.gov or the EU trials register (CTIS). The lead drug of each trial is used; placebo and standard-of-care arms are left out, and drug names are compared without doses or forms. A line says first when no earlier trial of the drug at that phase exists on either register, from any sponsor, and new otherwise. A new trial is a registration, not a result.
Sources: ClinicalTrials.gov, EU Clinical Trials Information System (CTIS).